SCHEMBL15086750

SCHEMBL15086750

COc1ccc(C2=NN(C(=O)c3cccc(C#N)c3)CC2c2ccccc2)cc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ CNR1 P21554 3/20 0.43
▸ PDE4A P27815 3/20 0.41
▸ PDE4B Q07343 3/20 0.41
▸ PDE4C Q08493 3/20 0.41
▸ PDE4D Q08499 3/20 0.41
▸ ABCG2 Q9UNQ0 1/20 0.41
▸ GRM5 P41594 2/20 0.41
▸ MAOA P21397 1/20 0.40
▸ MAOB P27338 1/20 0.40
▸ MCHR1 Q99705 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ DRD2 P14416 1/20 0.39
▸ DRD1 P21728 1/20 0.39
▸ DRD4 P21917 1/20 0.39
▸ DRD5 P21918 1/20 0.39
▸ DRD3 P35462 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15086754 0.95 KMT2A (0.44) KMT2AKDM4EALDH1A1HPGDCNR1
SCHEMBL15086742 0.92 KMT2A (0.41) KMT2AKDM4EALDH1A1HPGDCNR1
SCHEMBL15086753 0.87 KMT2A (0.47) KMT2AKDM4EALDH1A1HPGDCNR1
SCHEMBL15086792 0.87 SCD (0.43) KMT2AALDH1A1CNR1MCHR1
SCHEMBL15086749 0.86 SCD (0.49) KMT2AKDM4EALDH1A1HPGDCNR1
SCHEMBL15086769 0.85 KMT2A (0.44) KMT2AKDM4EALDH1A1HPGDCNR1
SCHEMBL15086756 0.84 KMT2A (0.44) KMT2AKDM4EALDH1A1HPGDPDE4A
SCHEMBL15086751 0.84 PDE4A (0.47) KMT2AKDM4EALDH1A1HPGDCNR1
SCHEMBL15086752 0.79 KMT2A (0.43) KMT2AKDM4EALDH1A1HPGDCNR1
SCHEMBL15086799 0.79 SCD (0.45) KMT2AALDH1A1CNR1PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170368030-A1 Dihydropyrazoles MERCK PATENT GMBH (DE) 2017-12-28 — — US disclosed
US-9775830-B2 Dihydropyrazoles MERCK PATENT GMBH (DE) 2017-10-03 — — US disclosed
US-9775830-B2 Dihydropyrazoles MERCK PATENT GMBH (DE) 2017-10-03 — — US disclosed
US-20170071910-A1 Dihydropyrazoles MERCK PATENT GMBH (DE) 2017-03-16 — — US disclosed
US-20170071910-A1 Dihydropyrazoles MERCK PATENT GMBH (DE) 2017-03-16 — — US disclosed
US-9517227-B2 Dihydropyrazoles MERCK PATENT GMBH (DE) 2016-12-13 — — US disclosed
US-9517227-B2 Dihydropyrazoles MERCK PATENT GMBH (DE) 2016-12-13 — — US disclosed
US-20140296238-A1 Dihydropyrazoles MERCK PATENT GMBH (DE) 2014-10-02 — — US disclosed
US-20140296238-A1 Dihydropyrazoles MERCK PATENT GMBH (DE) 2014-10-02 — — US disclosed
US-8791114-B2 Dihydropyrazoles MERCK PATENT GMBH (DE) 2014-07-29 — — US disclosed
US-8791114-B2 Dihydropyrazoles MERCK PATENT GMBH (DE) 2014-07-29 — — US disclosed
US-20130172351-A1 Dihydropyrazoles MERCK PATENT GMBH (DE) 2013-07-04 — — US disclosed
US-20130172351-A1 Dihydropyrazoles MERCK PATENT GMBH (DE) 2013-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170368030-A1 Dihydropyrazoles FSHR, GNRHR, LHCGR KMT2A 2373/4885KDM4E 1428/4885ALDH1A1 3510/4885
US-20130172351-A1 Dihydropyrazoles FSHR, GNRHR, LHCGR KMT2A 2373/4885KDM4E 1428/4885ALDH1A1 3510/4885
US-20140296238-A1 Dihydropyrazoles FSHR, GNRHR, LHCGR KMT2A 2373/4885KDM4E 1428/4885ALDH1A1 3510/4885
US-20170071910-A1 Dihydropyrazoles FSHR, GNRHR, LHCGR KMT2A 2373/4885KDM4E 1428/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback